ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Eisai-Biogen Alzheimer's drug set for use at 300-plus US hospitals: exec

Head of Japanese drugmaker's neurology division bullish on pricey Aduhelm

Some U.S. medical centers have begun administering Aduhelm to patients, an Eisai executive says. (AP/Kyodo)

TOKYO -- The Alzheimer's disease drug developed by Tokyo-based Eisai and U.S. partner Biogen is set to be used by more than 300 American medical institutions and is already being administered to some patients, the head of Eisai's neurology business told Nikkei on Tuesday.

Aducanumab, marketed under the brand name Aduhelm, received conditional approval from the U.S. Food and Drug Administration in June under a cloud of doubts. The drug targets plaques in the brain formed by amyloid proteins, believed to be a major cause of Alzheimer's-related dementia.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more